Trump announces trade deal with EU following months of negotiations
STONY BROOK, NY - Applied DNA Sciences, Inc. (NASDAQ:APDN), a micro-cap company with a market value of $2.74 million, has received a seventh follow-on order valued at more than $600,000 for its LineaDNA product, the company announced Thursday. According to InvestingPro data, the company maintains a strong liquidity position, holding more cash than debt on its balance sheet.
The order was placed by a global manufacturer of in vitro diagnostics under an existing supply agreement. The LineaDNA will be used as a functional component in a cancer diagnostic test, according to the company’s press release.
Deliveries are scheduled across four quarterly shipments beginning in the second quarter of fiscal 2026, which ends March 31, 2026.
LineaDNA is described as a cell-free DNA production system that produces high-fidelity DNA without adventitious sequences. The platform can generate DNA from 100 base pairs to 20 kilobases in varying quantities and quality grades.
Applied DNA Sciences specializes in polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the company commercializes platforms for manufacturing nucleic acid-based therapies.
The company’s LineaDNA platform differs from conventional plasmid-based DNA production methods by offering rapid scalability and amenability to chemical modification, according to the statement.
Applied DNA Sciences trades on the Nasdaq Capital Market under the ticker APDN. While InvestingPro analysis suggests the stock is currently undervalued, investors should note that analysts do not anticipate profitability this year. For detailed insights and 10+ additional ProTips about APDN, including comprehensive financial health metrics, explore the full Pro Research Report available on InvestingPro.
In other recent news, Applied DNA Sciences, Inc. has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company received confirmation from Nasdaq that it meets the $1.00 minimum bid price requirement, leading to the cancellation of a previously scheduled hearing before the Nasdaq Hearings Panel. Additionally, Applied DNA Sciences announced a strategic restructuring that involves a 27% reduction in its workforce and the closure of its Applied DNA Clinical Labs business. This move is part of a realignment to concentrate on its synthetic DNA manufacturing business, LineaRx. The company also appointed Judy Murrah as the new Chairperson and CEO, succeeding Dr. James A. Hayward, who is retiring after two decades with the company. Murrah will continue to serve as President while leading the executive management team. These developments mark significant changes for Applied DNA Sciences as it navigates its strategic focus and leadership transition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.